The University of Chicago Header Logo

Connection

Barry G. Arnason to Interferon beta-1b

Back to Details
This is a "connection" page, showing publications Barry G. Arnason has written about Interferon beta-1b.
Barry G. Arnason
Connection Strength
0.882
Interferon beta-1b
  1. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019 04; 25(4):565-573.
    View in: PubMed
    Score: 0.139
  2. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65.
    View in: PubMed
    Score: 0.119
  3. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71.
    View in: PubMed
    Score: 0.116
  4. MS Forum/MS Over the Past 17 Years. Int MS J. 2011 Sep; 17(3):76-82.
    View in: PubMed
    Score: 0.088
  5. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
    View in: PubMed
    Score: 0.078
  6. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. J Neurol. 2005 Sep; 252 Suppl 3:iii28-iii33.
    View in: PubMed
    Score: 0.058
  7. Immunologic therapy of multiple sclerosis. Annu Rev Med. 1999; 50:291-302.
    View in: PubMed
    Score: 0.037
  8. Role of interferons in demyelinating diseases. J Neural Transm Suppl. 1997; 49:117-23.
    View in: PubMed
    Score: 0.032
  9. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol. 1996 Oct; 81(1):1-11.
    View in: PubMed
    Score: 0.031
  10. Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study. Eur Neurol. 2014; 71(3-4):173-9.
    View in: PubMed
    Score: 0.026
  11. Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. J Neurol. 2013 Jul; 260(7):1838-45.
    View in: PubMed
    Score: 0.025
  12. Variability in detection and quantification of interferon ß-1b-induced neutralizing antibodies. J Neuroinflammation. 2012 Jun 15; 9:129.
    View in: PubMed
    Score: 0.023
  13. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95.
    View in: PubMed
    Score: 0.022
  14. Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult Scler. 2011 Dec; 17(12):1504-13.
    View in: PubMed
    Score: 0.022
  15. Interferon ß-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011 Apr 05; 76(14):1222-8.
    View in: PubMed
    Score: 0.021
  16. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
    View in: PubMed
    Score: 0.019
  17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12.
    View in: PubMed
    Score: 0.018
  18. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996 Jan; 46(1):12-8.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.